Search Results - "Mactier, S."

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Proteomic characterization and cross species comparison of mammalian seminal plasma

    Proteomic characterization and cross species comparison of mammalian seminal plasma by Druart, X., Rickard, J.P., Mactier, S., Kohnke, P.L., Kershaw-Young, C.M., Bathgate, R., Gibb, Z., Crossett, B., Tsikis, G., Labas, V., Harichaux, G., Grupen, C.G., de Graaf, S.P.

    Published in Journal of proteomics (08-10-2013)
    “…Seminal plasma contains a large protein component which has been implicated in the function, transit and survival of spermatozoa within the female reproductive…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    P17.47 COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME

    P17.47 COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME by Kaufman, K. L., Ly, L., McKay, M., Mallawaaratchy, D. M., Mactier, S., Crossett, B., Molloy, M., Buckland, M. E., McDonald, K. L., Christopherson, R. I.

    Published in Neuro-oncology (Charlottesville, Va.) (01-09-2014)
    “…Drugs that impair tumour angiogenesis, i.e. therapeutic antibody anti-vascular endothelial growth factor, bevacizumab (BEV), are becoming standard therapy for…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia

    4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia by Huang, Pauline Y, Best, O. Giles, Mactier, S, Majid, Aneela, Dyer, Martin, Mulligan, Stephen P, Christopherson, Richard I

    Published in Clinical lymphoma, myeloma and leukemia (01-10-2011)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    P17.47COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME

    P17.47COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME by Kaufman, K.L., Ly, L., McKay, M., Mallawaaratchy, D.M., Mactier, S., Crossett, B., Molloy, M., Buckland, M.E., McDonald, K.L., Christopherson, R.I.

    Published in Neuro-oncology (Charlottesville, Va.) (01-09-2014)
    “…Drugs that impair tumour angiogenesis, i.e. therapeutic antibody anti-vascular endothelial growth factor, bevacizumab (BEV), are becoming standard therapy for…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    PRS33 DEVELOPMENT OF A PREFERENCE-BASED ALGORITHM TO REPORT UTILITIES FOR EXACERBATIONS OF COPD FROM THE EXACT

    PRS33 DEVELOPMENT OF A PREFERENCE-BASED ALGORITHM TO REPORT UTILITIES FOR EXACERBATIONS OF COPD FROM THE EXACT by Petrillo, J, Mactier, S, Davies, E, Cairns, JA

    Published in Value in health (2009)
    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53

    Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53 by Almazi, Juhura G., Mactier, Swetlana, Best, O. Giles, Crossett, Ben, Mulligan, Stephen P., Christopherson, Richard I.

    Published in Proteomics. Clinical applications (01-06-2012)
    “…Purpose Human Raji cells treated with fludarabine nucleoside (2‐FaraA, 3 μM) undergo apoptosis with accumulation of p53 in the nuclei as multiple…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  7. 7
    Cell Surface Oncoproteomics: Cancer Biomarker Discovery and Clinical Applications

    Cell Surface Oncoproteomics: Cancer Biomarker Discovery and Clinical Applications

    Published in Oncoproteins: Types and Detection (2010)
    Get full text
    Book Chapter
    Save to List
    Saved in:

Search Tools: